Tilray | TRLY - Cost Of Sales

Stock Price
1.53
Daily Change
-0.11 -6.71%
Monthly
20.47%
Yearly
-34.05%
Q3 Forecast
1.63

Tilray reported $149.73M in Cost of Sales for its fiscal quarter ending in November of 2024.



Financials
Stock Price USD
Assets USD 4.19B
Cash and Equivalent USD 189.7M
Cost of Sales USD 149.73M
Current Assets USD 707.34M
Current Liabilities USD 278.52M
Debt USD 351.72M
EBIT USD -42.22M
EBITDA USD -101K
Employees USD 2.65K
EPS Earnings Per Share USD -1.78
Equity Capital and Reserves USD 3.47B
Gross Profit on Sales USD 61.22M
Interest Expense on Debt USD 7.77M
Interest Income USD 12.83M
Loan Capital USD 316.63M
Market Capitalization USD 1.18B
Net Income USD -85.34M
Operating Expenses USD 253.17M
Operating Profit USD -42.22M
Ordinary Share Capital USD 93K
Pre-Tax Profit USD -83.24M
Sales Revenues USD 308.01M
Selling and Administration Expenses USD 72.38M
Stock USD 266.01M
Trade Creditors USD 99.08M
Trade Debtors USD 112.74M

Cost Of Sales Change Date
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 70.07M 8.78M Jun/2025
Avita Medical AUD 2.28M 170K Dec/2024
Canopy Growth CAD 54.1M 3.44M Jun/2025
Cronos Group USD 19.65M 1.12M Jun/2025
Divis Laboratories Ltd 10.68B 870M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
IQVIA Holdings USD 2.97B 439M Jun/2025
Knight Therapeutics CAD 47.25M 990K Sep/2024
Moderna USD 119M 29M Jun/2025
Organigram Holdings CAD 44.65M 2.96M Jun/2025
Organon & Co USD 720M 48M Jun/2025
Revvity USD 327.73M 38.51M Jun/2025
Tilray USD 149.73M 9.39M Nov/2024
Viatris USD 2.25B 229.7M Jun/2025
Xeris Pharmaceuticals USD 11.9M 2.42M Jun/2025